Search Results - "de Albuquerque Rocha, Natalia"

  • Showing 1 - 12 results of 12
Refine Results
  1. 1

    Impact of empagliflozin in patients with diabetes and heart failure by Pham, David, MD, Albuquerque Rocha, Natalia De, MD, McGuire, Darren K., MD MHSc, Neeland, Ian J., MD

    Published in Trends in cardiovascular medicine (01-02-2017)
    “…Abstract Heart failure (HF) is a common disease with increased risk for mortality and morbidity among patients with type 2 diabetes mellitus (T2DM). Optimal…”
    Get full text
    Journal Article
  2. 2

    A randomized clinical trial evaluating the effect of empagliflozin on triglycerides in obese adults: Role of visceral fat by Lee, Min Hee, Neeland, Ian J., de Albuquerque Rocha, Natalia, Hughes, Connor, Malloy, Craig R., Jin, Eunsook S.

    Published in Metabolism open (01-03-2022)
    “…Empagliflozin, a sodium glucose cotransporter 2 inhibitor, is a medication to treat type 2 diabetes. The effect of empagliflozin in persons without diabetes…”
    Get full text
    Journal Article
  3. 3

    Effects of Empagliflozin Treatment on Glycerol‐Derived Hepatic Gluconeogenesis in Adults with Obesity: A Randomized Clinical Trial by Neeland, Ian J., Albuquerque Rocha, Natalia, Hughes, Connor, Ayers, Colby R., Malloy, Craig R., Jin, Eunsook S.

    Published in Obesity (Silver Spring, Md.) (01-07-2020)
    “…Objective The aim of this study was to determine the effects of empagliflozin on glycerol‐derived hepatic gluconeogenesis in adults with obesity without type 2…”
    Get full text
    Journal Article
  4. 4

    Should Metformin Remain First-Line Medical Therapy for Patients with Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease? An Alternative Approach by Harrington, Josephine L., de Albuquerque Rocha, Natalia, Patel, Kershaw V., Verma, Subodh, McGuire, Darren K.

    Published in Current diabetes reports (01-09-2018)
    “…Purpose of Review With recent cardiovascular outcome trial (CVOT) results for antihyperglycemic medications, the treatment algorithm for patients with type 2…”
    Get full text
    Journal Article
  5. 5

    Effects of sodium glucose co-transporter 2 inhibitors on the kidney by de Albuquerque Rocha, Natalia, Neeland, Ian J, McCullough, Peter A, Toto, Robert D, McGuire, Darren K

    Published in Diabetes & vascular disease research (01-09-2018)
    “…Sodium-glucose cotransporter 2 inhibitors are antihyperglycaemic medications with an emerging evidence base for cardiovascular and kidney disease risk…”
    Get more information
    Journal Article
  6. 6
  7. 7

    Diabetes medications and cardiovascular outcome trials: Lessons learned by Patel, Kershaw V, de Albuquerque Rocha, Natalia, McGuire, Darren K

    Published in Cleveland Clinic journal of medicine (01-10-2017)
    “…The US Food and Drug Administration's current standards require that new diabetes medications demonstrate cardiovascular safety in large, long-term trials. New…”
    Get full text
    Journal Article
  8. 8

    Contribution of ApoCIII to Diabetic Dyslipidemia and Treatment With Volanesorsen by Zhang, Jun, Rocha, Natalia de Albuquerque, McCullough, Peter A

    Published in Reviews in cardiovascular medicine (30-03-2018)
    “…Diabetic dyslipidemia in type 2 diabetes (T2DM) is characterized by elevated levels of triglycerides (TG), decreased levels of high density…”
    Get full text
    Journal Article
  9. 9
  10. 10
  11. 11

    Lithium nephrotoxicity by Oliveira, Jobson Lopes de, Silva Júnior, Geraldo Bezerra da, Abreu, Krasnalhia Lívia Soares de, Rocha, Natália de Albuquerque, Franco, Luiz Fernando Leonavicius G, Araújo, Sônia Maria Holanda Almeida, Daher, Elizabeth de Francesco

    “…Lithium has been widely used in the treatment of bipolar disorder. Its renal toxicity includes impaired urinary concentrating ability and natriuresis, renal…”
    Get more information
    Magazine Article
  12. 12